FDA Panel Votes Against Primatene Reboot Due To Safety Concerns

Concerns about safety prompt an FDA advisory panel to recommend against approving Armstrong Pharmaceutical’s NDA for an OTC emergency asthma inhaler. Concerns about device malfunction and about a potentially inaccurate dose indicator also influence the panel.